preclinical_heavy
Preclinical evidence exceeds central human evidence. Interpret translational relevance cautiously.
supportedtophigh inflation risk
Escherichia coli
inflammatory bowel disease
Escherichia coli has meaningful literature visibility in inflammatory bowel disease, but the current evidence mix suggests a substantial risk of overclaiming.
Escherichia coli shows a moderate evidence base in inflammatory bowel disease, with multiple central papers and additional supporting literature.
escherichia_coli
Credibility score
64
Human translation
2/5
Reproducibility
5/5
Novelty
1/5
Actionability
3/5
Credibility 64Human translation 2/5Reproducibility 5/5Novelty 1/5Actionability 3/5
Why this scores the way it does
- moderate central evidence base
- dense review literature
- substantial preclinical support
Main caveats
- preclinical evidence outweighs human evidence
- retrieval noise or disease-specificity issues may remain
Internal review flags
2 flagsreview_heavy
Review literature is very dense relative to primary central evidence.
Primary central evidence
13 papersEscherichia coli isolates from patients with inflammatory bowel disease: ExPEC virulence- and colicin-determinants are more frequent compared to healthy controls.
2018International journal of medical microbiology : IJMM
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Expansion of Bacteriophages Is Linked to Aggravated Intestinal Inflammation and Colitis.
2019Cell host & microbe
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Phylogenetic and pathotype analysis of Escherichia coli stool isolates from Egyptian patients with inflammatory bowel disease.
2019Germs
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Escherichia coli Strains from Patients with Inflammatory Bowel Diseases have Disease-specific Genomic Adaptations.
2022Journal of Crohn's & colitis
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Phylogrouping and characterization of Escherichia coli isolated from colonic biopsies and fecal samples of patients with flare of inflammatory bowel disease in Iran.
2022Frontiers in medicine
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Differentiation of Escherichia fergusonii and Escherichia coli Isolated from Patients with Inflammatory Bowel Disease/Ischemic Colitis and Their Antimicrobial Susceptibility Patterns.
2023Antibiotics (Basel, Switzerland)
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
High prevalence of Mucosa-Associated extended-spectrum β-Lactamase-producing Escherichia coli and Klebsiella pneumoniae among Iranain patients with inflammatory bowel disease (IBD).
2023Annals of clinical microbiology and antimicrobials
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Inflammatory bowel disease biomarkers revealed by the human gut microbiome network.
2023Scientific reports
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Mechanistic Implications of the Mediterranean Diet in Patients With Newly Diagnosed Crohn's Disease: Multiomic Results From a Prospective Cohort.
2025Gastroenterology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Engineered Probiotics Enable Targeted Gut Delivery of Dual Gasotransmitters for Inflammatory Bowel Disease Therapy.
2025Angewandte Chemie (International ed. in English)
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Structural Variations in Ulcerative Colitis-associated Escherichia coli Reduce Fructose Utilization and Aggravate Inflammation Under High-Fructose Diet.
2025Gastroenterology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Genetic and Microbial Analysis of Invasiveness for Escherichia coli Strains Associated With Inflammatory Bowel Disease.
2025Cellular and molecular gastroenterology and hepatology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Fecal gut microbiota and amino acids as noninvasive diagnostic biomarkers of Pediatric inflammatory bowel disease.
2025Gut microbes
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Preclinical supporting evidence
15 papersInterleukin-11.
1997BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Intestinal inflammation targets cancer-inducing activity of the microbiota.
2012Science (New York, N.Y.)
Disease-relevant preclinical or model-based paper useful as supporting evidence.
B. adolescentis ameliorates chronic colitis by regulating Treg/Th2 response and gut microbiota remodeling.
2021Gut microbes
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Programmable probiotics modulate inflammation and gut microbiota for inflammatory bowel disease treatment after effective oral delivery.
2022Nature communications
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Deferasirox alleviates DSS-induced ulcerative colitis in mice by inhibiting ferroptosis and improving intestinal microbiota.
2023Life sciences
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Engineered Escherichia coli for the in situ secretion of therapeutic nanobodies in the gut.
2023Cell host & microbe
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Escherichia coli Nissle 1917 ghosts alleviate inflammatory bowel disease in zebrafish.
2023Life sciences
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Polyphenolic Nanoparticle-Modified Probiotics for Microenvironment Remodeling and Targeted Therapy of Inflammatory Bowel Disease.
2024ACS nano
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Engineered probiotics with sustained release of interleukin-2 for the treatment of inflammatory bowel disease after oral delivery.
2024Biomaterials
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Gut virome-wide association analysis identifies cross-population viral signatures for inflammatory bowel disease.
2024Microbiome
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Alleviation of colitis by honeysuckle MIR2911 via direct regulation of gut microbiota.
2024Journal of controlled release : official journal of the Controlled Release Society
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Immunomolecular and reactivity landscapes of gut IgA subclasses in homeostasis and inflammatory bowel disease.
2024The Journal of experimental medicine
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Intestinal E. coli-produced yersiniabactin promotes profibrotic macrophages in Crohn's disease.
2025Cell host & microbe
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Orally Administered Functional Polyphenol-Nanozyme-Armored Probiotics for Enhanced Amelioration of Intestinal Inflammation and Microbiota Dysbiosis.
2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Bacterial membrane vesicles restore gut anaerobiosis.
2025NPJ biofilms and microbiomes
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Review supporting evidence
33 papersAdherent-invasive Escherichia coli in inflammatory bowel disease.
2007Inflammatory bowel diseases
Relevant review or meta-analysis for the signal-disease area.
Clinical use of E. coli Nissle 1917 in inflammatory bowel disease.
2008Inflammatory bowel diseases
Relevant review or meta-analysis for the signal-disease area.
Probiotics and prebiotics in inflammatory bowel disease: microflora 'on the scope'.
2008British journal of clinical pharmacology
Relevant review or meta-analysis for the signal-disease area.
Paediatric gastroenterology 1966-2000.
2008Clinical medicine (London, England)
Relevant review or meta-analysis for the signal-disease area.
Intestinal bacteria and inflammatory bowel disease.
2009Critical reviews in clinical laboratory sciences
Relevant review or meta-analysis for the signal-disease area.
Infectious colitis.
2011Current opinion in gastroenterology
Relevant review or meta-analysis for the signal-disease area.
Toxic megacolon.
2012Inflammatory bowel diseases
Relevant review or meta-analysis for the signal-disease area.
Escherichia coli-host macrophage interactions in the pathogenesis of inflammatory bowel disease.
2014World journal of gastroenterology
Relevant review or meta-analysis for the signal-disease area.
Intestinal microbiota, probiotics and prebiotics in inflammatory bowel disease.
2014World journal of gastroenterology
Relevant review or meta-analysis for the signal-disease area.
Colorectal cancer-inflammatory bowel disease nexus and felony of Escherichia coli.
2017Life sciences
Relevant review or meta-analysis for the signal-disease area.
Adherent-invasive Escherichia coli in inflammatory bowel disease.
2018Gut
Relevant review or meta-analysis for the signal-disease area.
Escherichia coli Pathobionts Associated with Inflammatory Bowel Disease.
2019Clinical microbiology reviews
Relevant review or meta-analysis for the signal-disease area.
Microbial genes and pathways in inflammatory bowel disease.
2019Nature reviews. Microbiology
Relevant review or meta-analysis for the signal-disease area.
New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD.
2020Autophagy
Relevant review or meta-analysis for the signal-disease area.
Prebiotics and Probiotics in Inflammatory Bowel Disease: Where are we now and where are we going?
2020Current clinical pharmacology
Relevant review or meta-analysis for the signal-disease area.
Alterations of the Skin and Gut Microbiome in Psoriasis and Psoriatic Arthritis.
2021International journal of molecular sciences
Relevant review or meta-analysis for the signal-disease area.
Shining a Light on Colibactin Biology.
2021Toxins
Relevant review or meta-analysis for the signal-disease area.
The influence of the gut microbiota on the bioavailability of oral drugs.
2021Acta pharmaceutica Sinica. B
Relevant review or meta-analysis for the signal-disease area.
Bacterial Species Associated With Human Inflammatory Bowel Disease and Their Pathogenic Mechanisms.
2022Frontiers in microbiology
Relevant review or meta-analysis for the signal-disease area.
Dietary Patterns and Gut Microbiota: The Crucial Actors in Inflammatory Bowel Disease.
2022Advances in nutrition (Bethesda, Md.)
Relevant review or meta-analysis for the signal-disease area.
Inflammatory Bowel Disease and COVID-19: How Microbiomics and Metabolomics Depict Two Sides of the Same Coin.
2022Frontiers in microbiology
Relevant review or meta-analysis for the signal-disease area.
Extracellular vesicles-mediated interaction within intestinal microenvironment in inflammatory bowel disease.
2022Journal of advanced research
Relevant review or meta-analysis for the signal-disease area.
Probiotic Escherichia coli NISSLE 1917 for inflammatory bowel disease applications.
2022Food & function
Relevant review or meta-analysis for the signal-disease area.
Intestinal phages interact with bacteria and are involved in human diseases.
2022Gut microbes
Relevant review or meta-analysis for the signal-disease area.
Gut microbiota, inflammatory bowel disease and colorectal cancer.
2022World journal of gastroenterology
Relevant review or meta-analysis for the signal-disease area.
Role of adherent invasive Escherichia coli in pathogenesis of inflammatory bowel disease.
2022World journal of clinical cases
Relevant review or meta-analysis for the signal-disease area.
Autophagy in colitis-associated colon cancer: exploring its potential role in reducing initiation and preventing IBD-Related CAC development.
2024Autophagy
Relevant review or meta-analysis for the signal-disease area.
Pathobionts in Inflammatory Bowel Disease: Origins, Underlying Mechanisms, and Implications for Clinical Care.
2024Gastroenterology
Relevant review or meta-analysis for the signal-disease area.
Review article: The complex interplay between diet and Escherichia coli in inflammatory bowel disease.
2023Alimentary pharmacology & therapeutics
Relevant review or meta-analysis for the signal-disease area.
Exploring the relationship between Faecalibacterium duncaniae and Escherichia coli in inflammatory bowel disease (IBD): Insights and implications.
2024Computational and structural biotechnology journal
Relevant review or meta-analysis for the signal-disease area.
Gut microbiota and metabolites as predictors of biologics response in inflammatory bowel disease: A comprehensive systematic review.
2024Microbiological research
Relevant review or meta-analysis for the signal-disease area.
Metabolic network of the gut microbiota in inflammatory bowel disease.
2024Inflammation and regeneration
Relevant review or meta-analysis for the signal-disease area.
Gut Microbiota Serves as a Crucial Independent Biomarker in Inflammatory Bowel Disease (IBD).
2025International journal of molecular sciences
Relevant review or meta-analysis for the signal-disease area.